Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. August 2018 04:00 ET | Quelle: AC Immune SA

AC Immune Announces Important Clinical Milestones for ACI-24 Vaccine in Alzheimer's Disease and Down Syndrome

Start of Phase 2 trial with ACI-24 in patients with mild Alzheimer's disease; first patient enrolled Recruitment completed for high-dose cohort of Phase 1b study with ACI-24 for Abeta-related...
08. August 2018 04:00 ET | Quelle: AC Immune SA

AC Immune Reports Second Quarter 2018 Financial Results and Corporate Update

New total cash position of approximately CHF 210 million that is expected to extend cash runway to Q3 2021, excluding potential incoming milestones Financial position strengthened after Q2 close...
31. Juli 2018 16:05 ET | Quelle: AC Immune SA

AC Immune Announces Successful Closing of Second Subscription Rights Offering

Gross Proceeds of All Three Offerings of 10 Million Common Shares in Total Aggregate to USD 117.5 Million Lausanne, Switzerland, July 31, 2018 - AC Immune, SA (NASDAQ: ACIU), a Swiss-based,...
25. Juli 2018 17:55 ET | Quelle: AC Immune SA

New Phase 2 Data Analysis for Crenezumab Presented at Global Alzheimer's Conference Provides Strong Evidence for Engagement of the Principle Abeta Target

Crenezumab significantly reduces Abeta oligomers in cerebrospinal fluid (CSF) in patients with Alzheimer's disease Strong evidence for principal target engagement of Abeta oligomers, the most...
23. Juli 2018 20:30 ET | Quelle: AC Immune SA

AC Immune Announces Closing of First Subscription Rights Offering and Primary Offering as well as Full Exercise of Option to Purchase Additional Shares

Lausanne, Switzerland, July 24, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company focused on neurodegenerative diseases, today announced the closing of...
18. Juli 2018 19:16 ET | Quelle: AC Immune SA

AC Immune Announces Price of USD 11.75 for Offerings and Issuance of up to 10 Million Common Shares

Lausanne, Switzerland, July 19, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company focused on neurodegenerative diseases, today announced the price per...
17. Juli 2018 16:08 ET | Quelle: AC Immune SA

AC Immune Announces Offerings and Issuance of up to 10 Million Common Shares

Lausanne, Switzerland, July 17, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company focused on neurodegenerative diseases, today announced that it is...
17. Juli 2018 04:00 ET | Quelle: AC Immune SA

Crenezumab's Second Phase 3 Trial (CREAD 2) Fully Recruited - Updates on AC Immune's Pipeline and Technology Platforms to be presented at AAIC in Chicago

Crenezumab's Second Phase 3 Trial (CREAD 2) Fully Recruited-Updates on AC Immune's Pipeline and Technology Platforms to be presented at the Alzheimer's Association International Conference in...
06. Juli 2018 07:18 ET | Quelle: AC Immune SA

AC Immune Announces Results of Annual General Meeting

Lausanne, Switzerland, July 6, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that the...
02. Mai 2018 04:00 ET | Quelle: AC Immune SA

AC Immune Reports First Quarter 2018 Financial Results and Corporate Update

Announced first-in-human study for an alpha-synuclein PET tracer for Parkinson's disease Selected Tau small molecules (Tau Morphomers) have entered into IND/CTA* enabling studies; Phase 1 to...

Vorherige Seite